Contineum Therapeutics (Contineum Therapeutics) Total Stockholders Equity : $-75.63 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Total Stockholders Equity?

Contineum Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-75.63 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Contineum Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $-2.80. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Contineum Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.01.

Contineum Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Contineum Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Total Stockholders Equity Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Stockholders Equity

-70.89

-93.21

-67.94

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial			-93.21	-	-61.14	-67.94	-75.63

Contineum Therapeutics (NAS:CTNM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Contineum Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-75.629	-	0)	/	27.0558
	=	-2.80

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Contineum Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.474	+	0.111)	/	-75.629
	=	-0.01

Contineum Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024